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and Jürgen Götza,c,∗
aBrain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia
bAustralian Phenomics Facility (APF), John Curtin School of Medical Research, Australian National University,
Acton, ACT, Australia
cCentre for Ageing Dementia Research (CADR) at the Queensland Brain Institute (QBI),
The University of Queensland, Brisbane, QLD, Australia
Handling Associate Editor: Michal Novak
Accepted 20 March 2013
Abstract. One of the major challenges in neurodegenerative research is modeling systemic aging. Here, senescence-accelerated
mice such as the multigenic SAMP8 (senescence accelerated prone 8) mice are useful as they are characterized by an early
manifestation of senescence that includes a shortened lifespan and impaired brain and immune functions. While SAMP8 mice
are widely used tools to address aging and neurodegenerative conditions such as Alzheimer’s disease (AD), the underlying gene
mutations are not known. To make the SAMP8 strain a more versatile and useful research tool, we performed exome sequencing,
using SAMR1 (senescence accelerated mouse resistant 1) mice as controls. We identified 51 SNVs (single nucleotide variants)
that discriminate SAMP8 from SAMR1 mice. Using the prediction tool Polyphen2, we were able to subdivide the SNVs into
four categories: splice variants, probably damaging, possibly damaging, and benign. Of these genes, a significant fraction is
predicted to be expressed in the brain. Our data present these genes for a more detailed analysis in aging and neurodegeneration
studies. They underscore the usefulness of SAMP8 mice as an animal model to study fundamental mechanisms of both aging
and the pathogenesis of AD.
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INTRODUCTION
Aging is the major risk factor for a plethora of human
diseases. This includes Alzheimer’s disease (AD), a
neurodegenerative disorder that is characterized by a
progressive decline in memory and other cognitive
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sity of Queensland, Brisbane, QLD 4072, Australia. Tel.: +61 7 3346
6329; Fax: +61 7 3346 6301; E-mail: j.goetz@uq.edu.au.
functions, leading to dementia [1]. To better understand
the underlying pathogenic mechanisms and to develop
targeted therapies, a host of transgenic animal models
has been developed that reproduce amyloid plaques
and neurofibrillary tangles, the two brain lesions char-
acteristic of the human condition [2]. A prerequisite for
developing these lesions in mice has been the trans-
genic expression of the tau-encoding MAPT or the
amyloid- protein precursor (APP)-encoding APP
gene together with pathogenic mutations that are
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present in early-onset familial cases. The vast major-
ity of AD cases, however, are of late onset and hence,
transgenic models do not faithfully model these spo-
radic cases. Here, senescence-accelerated mice such
as the SAMP8 (senescence accelerated prone 8) strain
might be useful, as these mice display many features
known to occur early in the pathogenesis of AD, such
as increased oxidative stress and memory impairment
[3]. SAMP8 mice are therefore an excellent model
for studying the earliest neurodegenerative changes
associated with AD, providing a more encompassing
picture of human disease, a syndrome that is triggered
by a combination of age-related events [4].
Together with a series of related senescence-
accelerated mice, the SAMP8 strain was established
around 1975 by conventional inbreeding of AKR/J-
derived mice that displayed features of accelerated
aging such as hair loss, reduced activity, shortened
life expectancy, lordokyphosis (increased curvature
of the spine), and periophthalmic (around the eye)
problems [5]. Littermates of mice that did not
show a senescence-associated phenotype were also
inbred, and senescence-resistant, longer-lived SAMR
mice were obtained of which SAMR1 (senescence
accelerated mouse resistant 1) mice are commer-
cially available. SAMP strains exhibit an early onset
of age-related decline in the peripheral immunity
such as thymic involution, loss of CD4(+) T cells,
impaired helper T cell function, decreased antibody-
forming capacity, dysfunction of antigen-presenting
cells, decreased natural killer activity, increased auto-
antibodies, and susceptibility to viral infection [6].
SAMP8 mice have been extensively analyzed for
cognitive functions [7]. Impairment of spatial mem-
ory is initiated at the age of four months, as shown
by using various forms of water and radial arm mazes
[8–10]. By employing the more sensitive radial arm
water maze, impairments in spatial learning became
evident as early as three months of age [11]. In measur-
ing associative memories, fear conditioning or passive
avoidance tasks are widely used [12, 13]. In SAMP8
mice, while associative learning as assessed in the
fear conditioning-paradigm is not affected, both pas-
sive and active avoidance (i.e., learning to escape the
environment in which the aversive stimulus has been
received) are affected, with an age of onset as early as
two months [14, 15].
SAMP8 mice are neuropathologically characterized
by oxidative changes similar to those found in the AD
brain [16]. For example, key enzymes that detoxify
reactive oxygen species such as MnSOD, catalase or
glutathione peroxidase are all decreased in SAMP8
compared to SAMR1 mice [17–19]. Increased lipid
peroxidation and carbonyl damage is present as early as
2 months of age [20]. Furthermore, SAMP8 mice have
an impaired glucose metabolism [21], and reveal age-
dependent reductions of various receptors including
for NMDA [22]. Because in the AD brain, deposi-
tion of A leads to plaque formation and that of the
microtubule-associated protein tau to tangle forma-
tion, these two process have been extensively analyzed
in SAMP8 mice [23]. Tau was found to be hyper-
phosphorylated using a small set of phosphorylation
site-specific antibodies, but tau filament formation and
tangle formation has not been reported indicating that
the SAMP8 mice present with an early rather than a
more advanced tau pathology [23]. In phosphorylat-
ing tau and causing its aggregation [24], studies in
SAMP8 mice suggest a role for the kinases GSK3
and Cdk5 [25]. Staining with A-specific antibod-
ies suggested A deposition in the mice [26, 27];
however because different from the human sequence
of APP, the murine protein lacks the amino acids
that are required to generate A in the first place,
these deposits have been termed ‘A-like’ [26]. For
APP, age-related increases have been reported, both
at the protein and mRNA level [28–30]. Finally, a glial
pathology characterizes the aging brain and in par-
ticular, the AD brain, and not surprisingly, SAMP8
mice present with a marked astro- and microgliosis [30,
31]. These findings present SAMP8 mice as a suitable
model for aging dementia, thereby complementing the
existing transgenic mouse models.
However, a major drawback in making the best use
of senescence-accelerated mice is that their phenotype
is multigenic and that the underlying gene mutations
are not known. Therefore, we obtained SAMP8 mice
from a commercial breeder and phenotypically charac-
terized them. To make the SAMP8 model more suitable
for geriatric studies, we performed massively parallel
exome sequencing [32]. By applying this method to
SAMP8 and SAMR1 mice, we were able to identify
51 SAMP8-specific single nucleotide variants (SNVs),
followed by a Polyphen2 analysis that allows pheno-
type predictions.
MATERIALS AND METHODS
Animals
SAMP8/TaHsd (in short: SAMP8) and SAMR1/
TaHsd (in short: SAMR1) mice were obtained from
Harlan Laboratories UK Ltd. They were rederived by
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embryo transfer followed by expansion of a colony
in the SPF unit of our institute’s animal facility. Ani-
mal experimentation was approved by the Animal
Ethics Committee (AEC) of the University of Sydney
(approval number K00/1-2009/3/4914).
Phenotypic analysis and histology
The weight of the mice was monitored on a weekly
basis. Immunohistochemical staining for glial fibrillar
acidic protein (GFAP) was done on 3 m sections of
paraformaldehyde-fixed and paraffin-embedded brain
tissue of 6 month-old mice as described [33]. More
specifically, brains were fixed in paraformaldehyde
and embedded in paraffin using an Excalibur tissue
processor (Thermo). Antigen retrieval was done in a
temperature- and pressure-controlled microwave sys-
tem (Milestone) in Tris/EDTA pH 9.0 for 7 min at
120◦C, followed by cooling under running tap water
for 10 min. Primary antibody anti-GFAP (monoclonal
IgG, Sigma, #63893) was diluted 1 : 100 in block-
ing buffer (heat inactivated 3% normal goal serum,
2% BSA, 0.1% Tween-20 in 1 × PBS) and incubated
overnight at 4◦C. After three washes in 1 × PBS,
the sections were incubated with an Alexa-coupled
secondary antibody (Invitrogen, #A-11001) for 1 h
at room temperature, followed by three washes in
1 × PBS. The sections were then mounted in Fluoro-
mount medium (Sigma # F4680) and digital images
taken with a BX51 fluorescent microscope (Olympus).
Exome sequencing
Exome enriched, paired end libraries were prepared
from genomic DNA of two SAMP8 and two SAMR1
mice following the protocol ‘SureSelect Target Enrich-
ment System for Illumina Paired-End Multiplexed
Sequencing library’ (v1.1.1, November 2010, Agilent).
The Illumina Paired-end genomic DNA sample prep
kit (PE-102-1001, Illumina) was used for preparing
the libraries including end repair, A-tailing, and liga-
tion of the Illumina adaptors. For capture, SureSelect
Mouse exome baits (G7550, Agilent) were used to
enrich for the mouse exome. Each sample was pre-
pared with an index in an amplification step following
capture using the Illumina multiplexing sample prepa-
ration oligo-nucleotide kit (PE-400-1001, Illumina).
Enriched sample libraries were pooled in equimolar
batches of three and each batch run as 100 bp paired
end libraries on the Illumina HiSeq 2000 sequencer.
Data analysis
Sequence reads were mapped to the NCBIM37
assembly of the reference mouse genome using
Burrows-Wheeler Aligner (http://bio-bwa.sourceforge
.net) [34]. Untrimmed reads were aligned allowing
a maximum of two sequence mismatches and were
discarded where they aligned to the genome more
than once. Sequence variants were identified with
SAMtools (http://samtools.sourceforge.net) [35] and
annotated using Annovar (http://www.openbioinforma
tics.org) [36]. A version of PolyPhen2 (http://genetics.
bwh.harvard.edu/pph2) [37], adapted for the mouse,
was utilized for the calculation of the variant effect.
Validation of single nucleotide variants
SNVs identified by Next Generation Sequencing
were validated using the Amplifluor SNP genotyping
system (Chemicon, Millipore). Assays were designed
to each SNV of interest and validated against a
set of Samp8 and SamR1 mice. Primer sequences
for each SNV that has been assayed can be found
in the Supplementary Table 1 (available online:
http://dx.doi.org/10.3233/JAD-130089).
RESULTS
Phenotypic characterization of SAMP8 mice
To phenotypically characterize SAMP8 mice and
differentiate them from SAMR1 mice, we determined
the lifespan of both strains. According to Harlan from
whom we had obtained the mice, the median survival
time of SAMP8 mice is 12.1 months whereas SAMR1
mice have a median survival time of 18.9 months. Oth-
ers reported a mean lifespan of 9.7 months for SAMP
mice (not specifying the sub-strain) and 16.3 months
for SAMR mice, while standard inbred mouse strains
(such as C57Bl/6) have a life expectancy in the order
of 28 months [4]. In agreement with previous data, we
found that SAMP8 mice displayed an increased mor-
tality compared to SAMR1 mice (Fig. 1A), and gained
less weight as they aged (Fig. 1B). At six months of age,
using immunohistochemistry, we did not find evidence
for amyloid plaque formation in the SAMP8 compared
to the SAMR1 mice using the 4G8 antibody, nor did
we find pronounced differences in tau phosphoryla-
tion using antibodies 12E8, AT180, or AT8 (data not
shown). However, what we found at this age was a
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Fig. 1. Phenotypic characterization of SAMP8 mice. A) SAMP8 have an increased mortality compared to SAMR1 mice, (B) they are charac-
terized by a reduced weight gain due to reduced body musculature, and (C) already at an age of 6 months reveal pronounced astrogliosis as
evidenced by GFAP immunoreactivity. The pons is shown. For comparison, both strains revealed astrogliosis in the hippocampus but not the
cortex.
pronounced astrogliosis in the pons of SAMP8 com-
pared to SAMR1 mice (Fig. 1C). In the hippocampus,
the two strains showed a similar degree of astroglio-
sis, while cortical areas were, in our hands, virtually
free of activated astrocytes (data not shown). Pheno-
typically, by three to four months of age, SAMP8 mice
can be discriminated from SAMR1 mice based on their
reduced weight (Fig. 1B), a slightly hunched position,
skin coarseness, and partial alopecia, as shown for 6
month-old mice (Fig. 2A).
Exome sequencing of SAMP8 and SAMR1 DNA
To identify genes with a putative role in the SAMP8
phenotype, we performed exome sequencing of two
SAMP8 and SAMR1 mice each. Exome enrichment
allowed us to successfully sequence 85–90% of the
CCDS exome to a high level of coverage. From this
sequencing, we found 226 SNVs that were common
between the two SAMP8 mice and not seen in either
SAMR1 mice or in any previous sequencing effort
(>250 exomes, mostly C57Bl/6). By removing olfac-
tory and vomeronasal genes to eliminate a large subset
of possible SNV call errors due to the high sequence
homology amongst these gene family members, and
excluding genes with multiple SNVs (also indicating
short-read alignment errors rather than mutations) the
list was reduced to 113 SNVs.
Of the 113 SNVs, 105 were selected for validation
using a specific Amplifluor assay to each SNV on a
larger pool of SAMP8, SAMR1, C57Bl/6, and AKR/J
control samples (8 assays could not be designed with
primers of sufficient quality). Of the 103 SNVs, 37
were shared with the AKR/J control strain (i.e., a poly-
morphism between the C57Bl/6 reference genome and
the control AKR/J sample), 13 assays failed, 2 were
shown to be heterozygous and unique to SAMP8, 1
was a false positive, 1 was homozygous in the SAMP8
strain and heterozygous in all controls, and 51 SNVs
were unique to SAMP8 (Table 1). We found that the
SNVs were found on all chromosomes but 9, 16, and
Y. Most SNVs were found on chromosome 8 (a total
F. Delerue et al. / Exome Sequencing of Geriatric SAMP8 Mice 353
A B
Splice Probably damaging
Possibly damaging Benign
SAMR1 SAMP8
Polyphen2 prediction
C
splice        probably       possibly        benign
damaging     damaging  
Expression    Slight expr No expr No dataExpression    Slight expr No expr No data
Expression    Slight expr No expr No data Expression    Slight expr No expr No data
18
16
14
12
10
8
6
4
2
0
6
5
4
3
2
1
0
6
5
4
3
2
1
0
6 10
9
8
7
6
5
4
3
2
1
0
5
4
3
2
1
0
Fig. 2. Phenotype predictions. A) Partial alopecia shown for 6 month-old SAMP8 compared to SAMR1 mouse. B) Of the 51 SNVs that we
identified as being unique to SAMP8, 10 are possible splice variants, while 41 are within the coding sequence. According to the amino acid
substitution prediction tool Polyphen2, of the 41 coding variants, 24 are possibly or probably damaging (confidence of 0.5–1.0), while 17 are
probably benign (confidence <0.5). C) By consulting the Allen brain atlas, the four groups are either moderately or strongly expressed in brain,
not expressed or there are no data available.
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of ten), followed by chromosome 13 (five SNVs), and
4, 7, 10, and 19 (with four SNVs each).
Polyphen prediction of SAMP8-specific single
nucleotide variants and brain-specific expression
of SAMP8 genes
Of the 51 SNVs that we identified as being unique
to SAMP8, 10 are possible splice variants (intronic
mutations located within 10 base pairs of the exon
boundary), while 41 are within the coding sequence.
According to the amino acid substitution predic-
tion tool Polyphen2, of the 41 coding variants, 24
are possibly or probably damaging (confidence of
0.5–1.0), while 17 are probably benign (confidence
<0.5) (Table 1, Fig. 2B). The genes with SNVs have
multiple functions as suggested by a Gene Ontology
(GO) analysis (Table 2).
21 of the genes have an OMIM entry and 11 have
a reported phenotype in mice with a null mutation
(Table 2). By consulting the Allen brain atlas (Allen
Brain Atlas [Internet]. Seattle (WA): Allen Institute
for Brain Science. Copyright © 2009. Available from:
http://www.brain-map.org), we found that within the
first category (splice variants), 8 of 10 genes are
expressed in brain, while for 2 no expression was
reported (Table 3, Fig. 2C). For the second category
(probably damaging SNVs), for three genes, no data
are available, four are not expressed in brain, and nine
are expressed in brain, ranging from very slight to high
expression levels, and from a restricted expression pat-
tern to expression throughout the brain (Fig. 2C). For
the third category (possibly damaging), no data is avail-
able for one gene; and 7 genes are listed as being
expressed in brain. For the fourth category (benign),
for 1 no data are available on brain expression, 5 are not
expressed in brain, and 2 are slightly expressed in brain
(Fig. 2C). Overall, the data indicate that at least 50%
of all identified genes may have a function in the brain
(Fig. 2). Whether the SNVs cause changes in levels of
the encoded proteins, in their subcellular localization,
association with other proteins and/or in their activity,
remains to be determined in subsequent studies.
DISCUSSION
Characterized by a range of age-associated impair-
ments, which includes the nervous system, senescence-
accelerated SAMP8 mice present themselves as an
excellent geriatric model [38]. We confirmed that
SAMP8 mice die prematurely and that they display
a reduced weight gain compared to SAMR1 mice.
Astrogliosis has been suggested as a useful marker to
discriminate, at a pre-symptomatic age, the two strains;
however, we found this less reliable as in our studies
astrogliosis depended on the brain area investigated,
with both strains showing a similar degree of activa-
tion in the hippocampus, while SAMR1 mice showed
a much lesser degree of astrogliosis in the pons com-
pared to SAMP8 mice.
We also performed exome sequencing and identified
51 SNVs (mutations) that are unique to SAMP8 mice,
using senescence-resistant SAMR1 mice as well as the
two inbred strains C57Bl/6 and AKR/J (from which
SAMR1 and SAMP8 have been originally derived [5])
as controls. 10 of the SNVs are possible splice variants;
41 are within the coding sequence. Using the predic-
tion tool Polyphen2, we identified 24 of the 51 SNVs as
being either probably or possibly damaging. In com-
ing up with these predictions, it is not only the type
of amino acid that is critical but also where it sits in
relation to the different domains, such as binding and
active sites. Interestingly, not all A-T SNVs are benign,
as is the case, e.g., for SLC12A4.
As evidenced by GO analysis, the mutated genes
encode proteins with a wide range of cellular functions.
These include ion transport, cytokine activity, axono-
genesis, heme binding, GTP binding, protein transport,
and others. 21 of the genes have an OMIM entry and 11
have a reported phenotype in mice with a null muta-
tion. Consulting the Allen brain atlas revealed that a
significant fraction is expressed in the brain, often with
a regional pattern and ranging from very low to pro-
nounced expression levels. Overall, the data indicate
that at least 50% of all identified genes have a function
in the brain.
When we analyzed the genes with brain expres-
sion in more detail and restricted the analysis to those
SAMP8 SNVs for which the Polyphen tool either made
no predictions or predicted that they are ‘probably or
possibly damaging’, we identified several gene prod-
ucts that are worth being discussed in the context of the
known SAMP8 brain phenotype: APBA3 (also known
as Mint3) encodes an adapter protein that is part of
the X11 protein family. Interestingly, APBA3 interacts
with APP from which A is derived by proteolytic
cleavage. More recently APBA3 has been identified as
a mediator of APP signaling: Its interaction with a
set of transcriptional co-activators was shown to lead
to nuclear localization and transactivation, whereas an
interaction of the same set with Mint1 or Mint2 pre-
vented nuclear localization and transactivation [39].
There is increasing evidence that in AD gene regu-
latory networks are deregulated [40]: In the current
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Table 3
SAMP8-specific mutations and predictions of expression in brain. For the 51 SNVs that are unique to SAMP8 the genes are indicated we
assessed the expression in brain as provided by the Allen brain atlas (Allen Brain Atlas [Internet]. Seattle (WA): Allen Institute for Brain Science.
Copyright © 2009. Available from: http://www.brain-map.org): CTX, cortex; Hip, hippocampus; Olfact, olfactory bulb; Hypo, hypothalamus;
Crb, cerebellum; Thal, thalamus; pons, pallidum, and medulla. The MGI (Mouse Genome Informatics) link provides additional information on
the gene
Gene name Expression in brain Allen atlas link MGI Link
SYT11 All brain http://mouse.brain-map.org/experiment/show/
2649
http://www.informatics.jax.org/marker/
MGI:1859547
ARFIP2 CTX & Hip http://mouse.brain-map.org/experiment/show/
74990537
http://www.informatics.jax.org/marker/
MGI:1924182
TPP1 CTX & Hip http://mouse.brain-map.org/experiment/show/
68148756
http://www.informatics.jax.org/marker/
MGI:1336194
NAE1 Slight in CTX http://mouse.brain-map.org/experiment/show/
76098392
http://www.informatics.jax.org/marker/
MGI:2384561
TMEM208 No expression http://mouse.brain-map.org/experiment/show/
69015745
http://www.informatics.jax.org/marker/
MGI:1913570
EDC4 CTX & Hip http://mouse.brain-map.org/experiment/show/
68911011
http://www.informatics.jax.org/marker/
MGI:2446249
CNTNAP4 Very slight in Hip & Olfact http://mouse.brain-map.org/experiment/show/
68196926
http://www.informatics.jax.org/marker/
MGI:2183572
PARP8 CTX, Hip, & Hypo http://mouse.brain-map.org/experiment/show/
68445676
http://www.informatics.jax.org/marker/
MGI:1098713
6720463M24RIK No expression http://mouse.brain-map.org/experiment/show/
68797816
http://www.informatics.jax.org/marker/
MGI:1924994
KLF12 Slight in CTX & Olfact http://mouse.brain-map.org/experiment/show/
69289279
http://www.informatics.jax.org/marker/
MGI:1333796
SLC12A4 No expression http://mouse.brain-map.org/experiment/show/
69873797
http://www.informatics.jax.org/marker/
MGI:1309465
APBA3 Very slight in CTX http://mouse.brain-map.org/experiment/show/
68442913
http://www.informatics.jax.org/marker/
MGI:1888527
PQLC3 No data http://www.informatics.jax.org/marker/
MGI:2444067
TMEM55B CTX, Thal, Pons, Medulla http://mouse.brain-map.org/experiment/show/
69529095
http://www.informatics.jax.org/marker/
MGI:2448501
D15ERTD621E No expression http://mouse.brain-map.org/experiment/show/
71723906
http://www.informatics.jax.org/marker/
MGI:1277178
DNAHC8 No expression http://mouse.brain-map.org/experiment/show/
69626945
http://www.informatics.jax.org/marker/
MGI:107714
F830016B08RIK No data http://www.informatics.jax.org/marker/
MGI:3588218
FXN Very high, all brain http://mouse.brain-map.org/experiment/show/
69672575
http://www.informatics.jax.org/marker/
MGI:1096879
PTPRD CTX, Hip & Thal http://mouse.brain-map.org/experiment/show/
855
http://www.informatics.jax.org/marker/
MGI:97812
SPCS2 CTX, Pallidum & Hypo http://mouse.brain-map.org/experiment/show/
68667312
http://www.informatics.jax.org/marker/
MGI:1913874
IRS2 Very slight in Hip & Thal http://mouse.brain-map.org/experiment/show/
71211707
http://www.informatics.jax.org/marker/
MGI:109334
ODZ2 Very slight in Hip only http://mouse.brain-map.org/experiment/show/
79591631
http://www.informatics.jax.org/marker/
MGI:1345184
HBB-BH2 No data http://www.informatics.jax.org/marker/
MGI:96025
ANKRD2 No expression http://mouse.brain-map.org/experiment/show/
69526647
http://www.informatics.jax.org/marker/
MGI:1861447
4930506M07RIK CTX & Hip http://mouse.brain-map.org/experiment/show/
275675
http://www.informatics.jax.org/marker/
MGI:1918903
TESK1 Slight in CTX, Hip & Crb http://mouse.brain-map.org/experiment/show/
69980268
http://www.informatics.jax.org/marker/
MGI:1201675
D630023F18RIK No expression http://mouse.brain-map.org/experiment/show/
69609007
http://www.informatics.jax.org/marker/
MGI:2138198
PRL8A9 No expression http://mouse.brain-map.org/experiment/show/
71656664
http://www.informatics.jax.org/marker/
MGI:1914560
PCDH7 Very slight in CTX http://mouse.brain-map.org/experiment/show/
69782790
http://www.informatics.jax.org/marker/
MGI:1860487
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Table 3
(Continued)
Gene name Expression in brain Allen atlas link MGI Link
IFNA2 No data http://mouse.brain-map.org/experiment/show/
69526838
http://www.informatics.jax.org/marker/
MGI:107666
ARHGEF5 No expression http://mouse.brain-map.org/experiment/show/
69526838
http://www.informatics.jax.org/marker/
MGI:1858952
LRRC20 Very slight in Crb & Olfact http://mouse.brain-map.org/experiment/show/
68797500
http://www.informatics.jax.org/marker/
MGI:2387182
ZC3H12D No expression http://mouse.brain-map.org/experiment/show/
71809097
http://www.informatics.jax.org/marker/
MGI:3045313
1700019N19RIK No expression http://mouse.brain-map.org/experiment/show/
69114465
http://www.informatics.jax.org/marker/
MGI:1914757
ZFP352 No expression http://mouse.brain-map.org/experiment/show/
70785732
http://www.informatics.jax.org/marker/
MGI:2387418
LNX1 No expression http://mouse.brain-map.org/experiment/show/
74277745
http://www.informatics.jax.org/marker/
MGI:1278335
CDHR2 No expression http://mouse.brain-map.org/experiment/show/
69529107
http://www.informatics.jax.org/marker/
MGI:2687323
LOXHD1 No expression http://mouse.brain-map.org/experiment/show/
73514737
http://www.informatics.jax.org/marker/
MGI:1914609
GAS8 CTX, Hip & Thal http://mouse.brain-map.org/experiment/show/
74990538
http://www.informatics.jax.org/marker/
MGI:1202386
CAR7 No expression http://mouse.brain-map.org/experiment/show/
71496276
http://www.informatics.jax.org/marker/
MGI:103100
F12 No data http://www.informatics.jax.org/marker/
MGI:1891012
BANK1 Slight in CTX http://mouse.brain-map.org/experiment/show/
69528076
http://www.informatics.jax.org/marker/
MGI:2442120
JARID2 Slight in olfact http://mouse.brain-map.org/experiment/show/
605
http://www.informatics.jax.org/marker/
MGI:104813
BCAP31 CTX, Pons & Medulla http://mouse.brain-map.org/experiment/show/
79544798
http://www.informatics.jax.org/marker/
MGI:1350933
NLGN3 High all brain http://mouse.brain-map.org/experiment/show/
70300559
http://www.informatics.jax.org/marker/
MGI:2444609
WDR19 No expression http://mouse.brain-map.org/experiment/show/
70194988
http://www.informatics.jax.org/marker/
MGI:2443231
CES2G Very slight in olfact http://mouse.brain-map.org/experiment/show/
68445053
http://www.informatics.jax.org/marker/
MGI:1919611
PROM2 No expression http://mouse.brain-map.org/experiment/show/
68498519
http://www.informatics.jax.org/marker/
MGI:2138997
CALU No expression http://mouse.brain-map.org/experiment/show/
69013426
http://www.informatics.jax.org/marker/
MGI:1097158
PDP2 No expression http://mouse.brain-map.org/experiment/show/
70299983
http://www.informatics.jax.org/marker/
MGI:1918878
TBC1D30 Very slight in CTX http://mouse.brain-map.org/experiment/show/
72283432
http://www.informatics.jax.org/marker/
MGI:1921944
study, we also identified the enhancer of decapping
Edc4 [41], and Klf12 that encodes Kruppel-like Factor
12, a member of a zinc finger protein family that reg-
ulates gene transcription [42]. Interestingly, a recent
transcriptomic analysis of tau mutant mice revealed a
deregulation of several transcription factors including
Zranb1 (a Zinc finger-containing protein) and SFPQ
(splicing factor proline/glutamine rich), also known as
PSF (Polypyrimidine tract-binding protein-associated
Splicing Factor) [43]. Validation of SFPQ revealed that
in AD the transcription factor is relocalized from the
nucleus to the cytoplasm [43].
Among the genes with brain expression are several
that encode enzymes such as kinases and phosphatases
(PTPRD, TESK1, TMEM55B) that could potentially
regulate the phosphorylation of cytoskeletal proteins
such as tau. TESK1 is particularly interesting as
together with Spred1, it is an interaction partner of
the kinase MARKK/TAO1 that links the microtubule
and actin cytoskeleton [44]. With a SNV in the gene
encoding the signal peptidase SPCS2, more fundamen-
tal processes could be affected in the SAMP8 mice as
depletion of SPC3 in yeast leads to impaired secretion
and the accumulation of secretory proteins [45]. TPP1
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encodes the lysosomal enzyme tripeptidyl-peptidase 1,
and mutations in this gene cause a form of spinocere-
bellar ataxia, with patients having a shortened lifespan.
It might be possible, that the SNV found for TPP in the
SAMP8 mice contributes to the shortened lifespan that
characterizes the strain [46]. A SNV was also found
in the FXN gene, for which a trinucleotide expansion
in human causes yet another ataxia, Friedreich ataxia
[47].
Finally, IRS2 (insulin receptor signaling 2) is an
interesting molecule with central functions including
the regulation of mammalian lifespan and nutrient
homeostasis [48], glucose metabolism [49], as well as
mitochondrial functions and the dealing with oxidative
stress [50]. Moreover, IRS2 is a negative regula-
tor of memory formation and has been shown to
impair NMDA receptor-dependent long-term potenti-
ation [51, 52]. All of these functions are impaired in
the SAMP8 mice suggesting that an impaired IRS2
function could potentially contribute to the SAMP8
phenotype.
Having identified a total of 51 SNVs by exome
sequencing that discriminate SAMP8 and SAMR1, we
anticipate that these will allow a phenotypic discrim-
ination, especially as it is evident from our list that
several of the SNVs are within genes that in principal
could contribute to the SAMP8 phenotype. It is reason-
able to assume that a subset of the SNVs causes either
changes in protein levels, stability, subcellular local-
ization or posttransational modification of the encoded
proteins, which can be detected provided that suitable
antibodies are available. The SNVs should be also use-
ful in monitoring the SAMP8 strain to ensure that there
is no genetic drift in any given colony. Furthermore, it
may be possible to establish sub-lines that inherit some
of the SNVs and hence result in a segregation of a sub-
set of the phenotypic traits that affect selected systems
such as the brain or the immune system.
As mentioned above, SAMP8 mice do not present
with typical plaques and tangles, although the accu-
mulation of A and hyperphosphorylated tau has been
reported [23, 26]. In order to exploit SAMP8 mice
for AD research a further possibility is to cross the
SAMP8 mice with either A plaque-forming or tau
tangle-forming transgenic mice. Here, for example, the
question can be asked whether a tau pathology such as
that of P301L tau mutant mice with a memory pheno-
type [53] or of K369I mutant mice with neuronal loss
and a motor phenotype [54, 55] would be accelerated
by the presence of distinct SAMP8 SNVs. Alterna-
tively one could ask whether removing or reducing tau
would ameliorate some of the phenotypes that charac-
terize the SAMP8 mice [56]. In conclusion, we believe
that our data contribute to ascertaining SAMP8 mice as
a suitable model system to study aging and dementia.
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